Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AIS/Spectranetics

This article was originally published in The Gray Sheet

Executive Summary

Excimer laser manufacturers renew vows for merger; the latest agreement calls for Advanced Interventional Systems (LAIS) shareholders to receive .80282 shares of Spectranetics stock for each LAIS share, giving them 45% ownership of the new company. The merger, subject to "customary conditions" and shareholder approval, is expected to close in four months. Following the merger, Spectranetics' President and CEO Robert DePasqua would serve as President, CEO and a director of the new firm, while LAIS director David Goldsmith would serve as chairman. AIS Chairman and CEO Robert Wall has resigned. An earlier acquisition offer by Spectranetics and merger proposal by LAIS, which were floated after an initial merger agreement fell through, were terminated in December ("The Gray Sheet" Dec. 20, In Brief)
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT001794

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel